COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT

Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) entered a definitive agreement for a $2.6 million private placement, issuing 7,647,061 ordinary shares (or equivalents) plus series A and B warrants. Securities are priced at $0.34 per share and accompanying warrants, with closing expected on or about July 1, 2026.

Series A and B warrants, both with a $0.34 exercise price, cover up to 22,941,183 shares in total and become exercisable on the shareholder approval date. Net proceeds will fund working capital, R&D and evaluation of strategic transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• Private placement expected to raise approximately $2.6 million in gross proceeds
• Issuance of 7,647,061 shares plus warrants provides potential additional future capital
• Exercise price and purchase price aligned at $0.34 per share and warrant unit
• Net proceeds earmarked for working capital and R&D programs
• Company plans to use funds to evaluate strategic business combinations

Negative

• Equity deal includes 7,647,061 new shares plus warrants for up to 22,941,183 shares, increasing potential share count
• Securities are initially unregistered, limiting resale until SEC registration is effective
• Warrants have long durations, up to five years, extending potential future share issuance

News Market Reaction – CLGN

-4.83%

5 alerts

-4.83% News Effect

-20.6% Trough in 1 hr 30 min

-$268K Valuation Impact

$5.29M Market Cap

0.6x Rel. Volume

On the day this news was published, CLGN declined 4.83%, reflecting a moderate negative market reaction. Argus tracked a trough of -20.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $268K from the company's valuation, bringing the market cap to $5.29M at that time.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement secures roughly $2.6 million in gross proceeds via a discounted equity and warrant...

Analysis

This announcement secures roughly $2.6 million in gross proceeds via a discounted equity and warrant financing, bolstering cash for R&D and strategic deals. Investors may watch how issuance of over 7.6 million shares and warrants affects future capital needs.

Key Figures

Ordinary shares issued: 7,647,061 shares Series A warrants: 7,647,061 warrants Series B warrants: 15,294,122 warrants +5 more

8 metrics

Ordinary shares issued 7,647,061 shares Aggregate ordinary shares in the June 2026 private placement

Series A warrants 7,647,061 warrants Unregistered series A warrants issued in the private placement

Series B warrants 15,294,122 warrants Unregistered series B warrants issued in the private placement

Purchase price $0.34 per share Combined purchase price per ordinary share and accompanying warrants

Alt purchase price $0.3399 per share equivalent Per ordinary share equivalent and accompanying warrants

Warrant exercise price $0.34 per share Exercise price of both series A and series B warrants

Gross proceeds $2.6 million Expected gross proceeds from the June 2026 private placement

Expected closing date on or about July 1, 2026 Scheduled closing of the private placement, subject to conditions

Peers on Argus

CLGN traded up about 10% while only one momentum peer (PLUR) appeared, moving do...

1 Down

CLGN traded up about 10% while only one momentum peer (PLUR) appeared, moving down without news. Broader biotech peers show a mixed tape, pointing to a stock-specific reaction rather than a sector-wide move.

Historical Context

5 past events · Latest: May 29 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 29	Q1 2026 earnings	Negative	-0.7%	Weak Q1 2026 results with revenue drop and wider net loss.
Apr 13	Strategic update	Negative	-15.7%	AbbVie agreement termination and ~50% workforce reduction to extend runway.
Mar 26	2025 results	Positive	-12.0%	2025 revenue growth and narrowed net loss with cost reductions.
Mar 24	Nasdaq notice	Negative	+5.5%	Nasdaq minimum $1.00 bid price deficiency and cure-period disclosure.
Mar 18	Corporate website	Neutral	+1.7%	Launch of redesigned website highlighting rhCollagen platform and pipeline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent CLGN news has often led to downside, with occasional sharp divergences on financial and listing-related updates.

Regulatory & Risk Context

Short Interest: 0.2%

Short Interest

0.2% of float

0% 15% 30%+

low as of 2026-06-15 Days to cover: 1

Reported short interest appears low, suggesting limited squeeze dynamics and typically lower volatility driven by short covering alone.

Key Terms

private placement, series A warrants, series B warrants, registration statement, +2 more

6 terms

private placement financial

"unregistered series B warrants to purchase up to 15,294,122 ordinary shares, in a private placement at a combined"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

series A warrants financial

"unregistered series A warrants to purchase up to 7,647,061 ordinary shares and unregistered series B warrants"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

series B warrants financial

"ordinary shares and unregistered series B warrants to purchase up to 15,294,122 ordinary shares, in a private"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

registration statement regulatory

"expire two years after the effective date of a registration statement registering the shares issuable upon exercise"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

section 4(a)(2) regulatory

"made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

regulation d regulatory

"Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder, and applicable"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REHOVOT, Israel, June 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof), unregistered series A warrants to purchase up to 7,647,061 ordinary shares and unregistered series B warrants to purchase up to 15,294,122 ordinary shares, in a private placement at a combined purchase price of $0.34 per ordinary share and accompanying warrants (or $0.3399 per ordinary share equivalent and accompanying warrants). The series A warrants will have an exercise price of $0.34 per share, will be exercisable on the date of shareholder approval (the "Shareholder Approval Date") and will expire two years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The series B warrants will have an exercise price of $0.34 per share, will be exercisable on the Shareholder Approval Date and will expire five years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The private placement is expected to close on or about July 1, 2026, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.

 

 

The gross proceeds from the private placement, before deducting the placement agent's fees and other related expenses payable by the Company, are expected to be approximately $2.6 million. CollPlant intends to use the net proceeds for general corporate purposes including working capital and funding its research and development programs, and to continue evaluating strategic business combinations, including potential acquisitions, joint ventures, and other strategic transactions.

The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder, and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to the terms of the securities purchase agreement entered into with the investor, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") covering the resale of the ordinary shares and ordinary shares underlying the warrants sold in the private placement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

For more information about CollPlant, visit http://www.collplant.com.

Forward-Looking Statements

This press release may include forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to the completion of the private placement, the satisfaction of customary closing conditions related to the private placement, the intended use of proceeds from the private placement, statements relating to CollPlant's objectives plans and strategies and cash runway, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods, and including its ability to conclude a non-dilutive financing transaction; uncertainties regarding the Company's evaluation of strategic alternatives, including whether or when any acquisition, strategic transaction, business combination or other opportunity may be pursued or consummated, the terms of any such transaction, and the potential impact of any such transaction or other strategic alternative on the Company, its business, financial condition, results of operations and shareholders; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to dermal and tissue fillers, breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company's strategy and development plans and projects, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

CollPlant:
Eran Rotem
Deputy CEO & CFO
+972-73-2325600 
eran@collplant.com

View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-2-6-million-private-placement-302814339.html

SOURCE CollPlant

FAQ

What are the key terms of CollPlant (Nasdaq: CLGN) $2.6 million private placement announced June 30, 2026?

CollPlant agreed to sell 7,647,061 ordinary shares and series A and B warrants for about $2.6 million. According to CollPlant, the combined purchase price is $0.34 per share and accompanying warrants, with closing expected around July 1, 2026, subject to conditions.

How many shares and warrants are included in the new CollPlant (CLGN) private placement?

The transaction covers 7,647,061 ordinary shares (or equivalents) plus series A warrants for 7,647,061 shares and series B warrants for 15,294,122 shares. According to CollPlant, this totals potential issuance of up to 22,941,183 shares from warrants alone if fully exercised.

What are the exercise prices and expiry dates of CollPlant (CLGN) series A and B warrants?

Both warrant series have a $0.34 exercise price and become exercisable on the shareholder approval date. According to CollPlant, series A warrants expire two years after the related registration statement is effective, while series B warrants expire five years after that effective date.

How will CollPlant (CLGN) use the proceeds from the June 2026 private placement?

CollPlant plans to use net proceeds for general corporate purposes, including working capital and R&D. According to CollPlant, funds will also support evaluation of strategic business combinations such as potential acquisitions, joint ventures and other strategic transactions in its regenerative and aesthetic medicine focus areas.

Is the June 30, 2026 CollPlant (CLGN) private placement registered with the SEC?

The securities are being sold in an unregistered private placement relying on exemptions from SEC registration. According to CollPlant, the company agreed to file a registration statement with the SEC to cover resale of the ordinary shares and warrant shares issued in this financing.

When will CollPlant (CLGN) private placement announced June 30, 2026 close, and who is the placement agent?

Closing is expected on or about July 1, 2026, subject to customary conditions. According to CollPlant, H.C. Wainwright & Co. is acting as the exclusive placement agent for this private placement of ordinary shares, series A warrants and series B warrants.